<![CDATA[Anbenitamab Regimen Meets Phase 3 End Points in HER2+ Breast Cancer]]>
Results from a phase 3 clinical trial evaluating anbenitamab (KN026; Ennituo) plus docetaxel for injection albumin-bound (HB1801) in patients with HER2-positive breast cancer met the prespecified primary end point of progression-free survival (PFS) …